Health Care · NASDAQ: BIIB
Biogen: how the business works
Biogen develops, makes and sells prescription medicines, mostly for multiple sclerosis and other nerve diseases, with revenue of $9.9 billion in FY2025.
By Hardik Bhandare · Checked against filings: . Editorial policy. Corrections
Follow Biogen
Email me when Biogen's page is updated after earnings.
We'll send a confirmation email first. See our privacy policy.
Biogen Inc. · Cambridge, Massachusetts · Founded 1978
Updated for Q3 FY2026 · checked
- Revenue, FY2025
- $9.9B
- Net income, FY2025
- $1.3B
- Revenue, Q3 FY2026
- $2.8B
- Staff, end of 2025
- About 7,500
- Founded
- 1978
The short version
Biogen in 5 points
1 · What it sells
Biogen sells prescription medicines, mostly for brain and nerve diseases, and its multiple sclerosis medicines brought in $4.04 billion of its $9.9 billion FY2025 revenue.
2 · Who pays it
In FY2025, US product sales were 35.9% of Biogen's revenue, product sales outside the US 36.1%, Genentech's payments 18.8%, contract manufacturing and royalties 7.4% and the Eisai LEQEMBI share 1.8%.
3 · What it keeps from $100
Of every $100 of revenue in FY2025, Biogen kept $13.1 as net income; it reports no operating income, and its EBITDAOperating profit before wear-and-tear charges (depreciation and amortization). As a margin: per $100 of sales. (profit before interest, tax and wear-and-tear), a Cityfort calculation, was $26.7 per $100.
4 · Where the operating profit comes from
Biogen reports one business segment and no profit by product; multiple sclerosis medicines were 40.8% of FY2025 revenue and rare disease medicines 21.8%.
5 · The one thing to watch
Multiple sclerosis medicines brought in $919 million in Q3 FY2026, down from $1.06 billion a year earlier, while the Apellis medicines added $243 million.
Sources: From Biogen's FY2025 10-K, Q3 FY2026 10-Q and Q3 FY2026 earnings release · checked
01Where the money goes · FY2025
Where does $100 of Biogen's money go?
Biogen · FY2025
Receipt for every $100
| Cost of sales | $24.3 |
|---|---|
| Research and development (incl. bought-in programs) | $22.7 |
| Selling, general and administrative | $24.6 |
| Amortization, partner profit shares and other charges | $9.5 |
| Other expense, net (interest) | $3.1 |
| Income tax | $2.7 |
| Kept as net income | $13.1 |
| Total | $100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly $100 because of rounding.
How this is worked out
Cityfort calculation from the FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $9.89 billion × 100. Biogen had no net other income that year, so revenue is all the money that came in. Research and development works out to $22.75 and is rounded down to $22.7 so the lines add to $100.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report earnings, explained in 5 points.
No tips. Unsubscribe anytime.
We'll send a confirmation email. See our privacy policy.
02The business in one line
What does Biogen do?
Distributors buy Biogen's medicines and Genentech pays it royalties; making, researching and selling the drugs take most of that money, and $13.1 of every $100 was left as net income in FY2025.
- In FY2025 Biogen sold $3.55 billion of medicines in the US and $3.57 billion outside it, and Genentech paid it $1.86 billion.
- Of every $100 of FY2025 revenue, selling and administration took $24.6, making the drugs $24.3 and research, including bought-in programs, $22.7 (rounded down from $22.75 so the lines add to $100).
03Who pays it
Who pays Biogen?
Wholesale and specialty distributors (US)
Share of revenue not disclosed
Buy Biogen's medicines and resell them to pharmacies and hospitals. US product revenue was $3.55 billion in FY2025, 49.8% of product revenue.
Health systems and distributors outside the US
Share of revenue not disclosed
Buy its medicines in Europe, Asia and other regions: $3.57 billion of product revenue in FY2025, $1.87 billion of it from Europe outside Germany.
Genentech (Roche group)
18.8%
of revenue
Pays the OCREVUS royalty and Biogen's share of US profits on RITUXAN, GAZYVA and LUNSUMIO: $1.86 billion in FY2025.
Contract manufacturing and royalty customers
7.4%
of revenue
Companies that pay Biogen to make their drugs, or pay it other royalties: $732.9 million in FY2025.
Eisai (LEQEMBI partnership)
1.8%
of revenue
Biogen's 50% share of LEQEMBI revenue and costs: $177.7 million in FY2025.
- Genentech (Roche group)18.8%
- Contract manufacturing and royalty customers7.4%
- Eisai (LEQEMBI partnership)1.8%
How spread out the customers are
Two wholesale distributors each bought more than 10% of Biogen's total revenue in FY2025, and together they took about 43.9% of gross product revenue, up from 36.9% in FY2023. Genentech payments were 18.8% of FY2025 revenue (Cityfort calculation from the FY2025 10-K).
Sources (1)
04How it makes money
How does Biogen make money?
Patent-protected medicines earn high profits until copies arrive, so Biogen must keep replacing them.
A new medicine is protected by patents for years, and that is when it earns most. Once generics or biosimilars launch, sales fall: TECFIDERA went from $1.01 billion in FY2023 to $680 million in FY2025. Biogen spends on research and buys companies such as Reata and Apellis to add new drugs.
Multiple sclerosis drugs, % of product revenue (Cityfort calculation from the FY2025 10-K)
64.3%56.7%
FY2023 to FY2025
- Research or buy a promising drug
- Win approval and patent protection
- Sell it at a high margin for years
- Patents end and cheaper copies arrive
- Sales of the old drug fall
- Spend the profits on the next drugs
↺ Step 6 feeds back into step 1.
Sources (1)
05Business segments · FY2025
Which businesses make up Biogen?
Multiple sclerosis medicines
40.8%TYSABRI, VUMERITY, TECFIDERA, AVONEX, PLEGRIDY and FAMPYRA. Biogen reports one business segment, so it gives no profit figure for any group.
Revenue $4.0B ($4,039M)
Rare disease medicines
21.8%SPINRAZA, SKYCLARYS and QALSODY.
Revenue $2.2B ($2,154M)
Anti-CD20 programs (Genentech)
18.8%OCREVUS royalty and a share of US profits on RITUXAN, GAZYVA and LUNSUMIO.
Revenue $1.9B ($1,861M)
Biosimilars
7.4%BENEPALI, IMRALDI, FLIXABI and others, mostly sold outside the US.
Revenue $729M
Contract manufacturing, royalty and other
7.4%Making drugs for other companies, plus other royalties.
Revenue $733M
ZURZUVAE and other products
2%ZURZUVAE for postpartum depression, plus small older products.
Revenue $197M
LEQEMBI share (Eisai)
1.8%Biogen's 50% share of the LEQEMBI partnership's revenue and costs.
Revenue $178M
How the mix changed
- Multiple sclerosis medicines
- Rare disease medicines
- Anti-CD20 programs (Genentech)
- Biosimilars
- Contract manufacturing, royalty and other
- ZURZUVAE and other products
- LEQEMBI share (Eisai)
Revenue by segment, FY2023 to FY2025.
US$
See the numbers
Sources (1)
06The numbers · Consolidated · US$
How has Biogen done?
Revenue
$9.9BFY2025
Revenue fell from $11.0 billion in FY2021 to $9.7 billion in FY2024 and was $9.9 billion in FY2025. Q3 FY2026 revenue of $2.8 billion was 11% above a year earlier.
US$
See the numbers
Net income
$1.3BFY2025
Net income was $3.0 billion in FY2022 and $1.3 billion in FY2025. Q3 FY2026 showed a $20.6 million loss, in a quarter with $283.8 million of acquired research and milestone costs.
US$
See the numbers
Net income for every $100 of revenue
$13.1FY2025
EBITDA is a Cityfort calculation from the FY2025 and FY2024 10-Ks (income before tax, plus other expense, net, plus depreciation and amortization), because Biogen reports no operating income line. It was $26.7 per $100 of revenue in FY2025; the FY2022 and FY2024 figures include one-off gains.
Net margin: $ of net income per $100 of revenue
See the numbers
Free cash flow
$2.1BFY2025
Free cash flow, cash from operations minus spending on property and equipment, was $3.4 billion in FY2021 and $1.1 billion in FY2022 (Cityfort calculation from the FY2021 and FY2022 10-Ks) and $2.1 billion in FY2025, as Biogen's Q4 FY2025 earnings release states.
US$ · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). Net income is the share belonging to the company's owners.
Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained · Stock-based compensation and dilution: pay that becomes shares
Sources (16)
- Form 10-K for FY2021
- Form 10-K for FY2022
- Form 10-K for FY2024
- Form 10-K for FY2023
- Form 10-K for FY2025
- Q4 FY2025 earnings release (Form 8-K, Exhibit 99.1)
- Form 10-Q for Q1 FY2024
- Form 10-Q for Q2 FY2024
- Form 10-Q for Q3 FY2024
- Q4 FY2024 earnings release (Form 8-K, Exhibit 99.1)
- Form 10-Q for Q1 FY2025
- Form 10-Q for Q2 FY2025
- Form 10-Q for Q3 FY2025
- Form 10-Q for Q1 FY2026
- Form 10-Q for Q2 FY2026
- Form 10-Q for Q3 FY2026
07Who runs it
Who runs Biogen, and did they deliver?
Christopher A. Viehbacher
President and Chief Executive Officer · since 2022
CEO since November 2022.
Robin C. Kramer
Executive Vice President and Chief Financial Officer · since 2025
CFO since March 2025; joined Biogen in 2018.
Priya Singhal
Executive Vice President, Head of Development · since 2023
Head of Development since January 2023. The FY2025 10-K says she rejoined Biogen in 2020 after first working there between 2012 and 2018.
Susan H. Alexander
Executive Vice President, Chief Legal Officer · since 2018
Chief Legal Officer since April 2018; joined Biogen in 2006.
Maria C. Freire
Chair of the Board · since 2026
Elected to follow Caroline Dorsa, who did not stand for re-election at the 2026 annual meeting.
What they said, and what happened
1 too early to tell · 1 delivered
Said on Feb 6, 2026
Expected FY2026 total revenue to fall by a mid-single-digit percentage from FY2025.
Too early to tellWhat happened
On Jul 29, 2026 Biogen changed this to a rise by a mid-single-digit percentage, and repeated it on Oct 28, 2026. Revenue for the first nine months of 2026 was $8.02 billion.
Said on Apr 29, 2026
Expected the Apellis acquisition to close in the second quarter of 2026.
DeliveredWhat happened
The deal closed on May 14, 2026.
Sources (8)
- Form 10-K for FY2025
- Form 8-K: board chair change (Items 5.02 and 8.01)
- Proxy statement (DEF 14A) for the 2026 annual meeting
- Q4 FY2025 earnings release (Form 8-K, Exhibit 99.1)
- Q2 FY2026 earnings release (Form 8-K, Exhibit 99.1)
- Q3 FY2026 earnings release (Form 8-K, Exhibit 99.1)
- Q1 FY2026 earnings release (Form 8-K, Exhibit 99.1)
- Form 8-K: Apellis acquisition completed, CVR agreement and credit agreement
08What could go wrong
What could go wrong for Biogen?
- Competition
MS medicines losing sales to copies
Generic TECFIDERA is sold at deep discounts, and a TYSABRI biosimilar was approved in 2023. MS revenue fell from $4.66 billion in FY2023 to $4.04 billion in FY2025; Biogen said in its FY2025 10-K (Feb 6, 2026) that it expects MS revenue to keep declining.
Watch Quarterly MS revenue: $919 million in Q3 FY2026, against $1.06 billion a year earlier.
- Concentration
OCREVUS royalty halves when a biosimilar arrives
The OCREVUS royalty was $1.41 billion in FY2025, 14.3% of revenue (Cityfort calculation from the FY2025 10-K). The tiered royalty on US OCREVUS sales falls by 50% once the first FDA-approved OCREVUS biosimilar launches; the $1.41 billion also includes a 3% royalty on OCREVUS sales outside the US.
Watch Any FDA approval of an OCREVUS biosimilar.
- Legal
Patent challenge to SPINRAZA
SPINRAZA was 15.6% of FY2025 revenue. Biogen has sued Somerset and Cipla over SPINRAZA patents, and trial is scheduled for May 2028.
Watch Court rulings in the Delaware SPINRAZA cases.
- Debt
Debt and integration after Apellis
Biogen's earnings releases put net debt at about $2.0 billion at Dec 31, 2025 and about $6.4 billion at Sep 30, 2026. Apellis integration restructuring cost about $194.7 million in the first nine months of 2026.
Watch Debt repayment and SYFOVRE sales, which set whether up to $4.00 per right is paid to former Apellis holders.
- Regulation
US drug price rules
The Inflation Reduction Act lets Medicare negotiate prices for some high-cost drugs: Part D from 2026 and Part B from 2028. Biogen's 10-Q also notes US actions on MFN (most-favored-nation) pricing that have been issued or proposed.
Watch Any Biogen medicine named for Medicare price negotiation in its filings.
- Execution
Drug trials may fail
Growth depends on new drugs. Biogen expensed $471.8 million on acquired research programs in FY2025 and $283.8 million in Q3 FY2026 alone.
Watch Phase 3 lupus results for litifilimab, due in the first half of December 2026, the company said.
- Concentration
Two distributors take a large share
Two wholesale distributors together accounted for about 43.9% of gross product revenue in FY2025.
Watch This share in the next 10-K.
09Supporters vs. critics
What do supporters and critics point to?
What supporters point to
- Revenue was $2.80 billion in Q3 FY2026, 11% above the $2.53 billion of Q3 FY2025.
- SPINRAZA sales were $461 million in Q3 FY2026, up from $374 million, after the FDA approved a higher-dose regimen in March 2026.
- SKYCLARYS, which came with Reata in 2023, grew from $55.9 million of sales in FY2023 to $520.5 million in FY2025.
- The Apellis medicines SYFOVRE and EMPAVELI added $243 million of revenue in Q3 FY2026.
- Free cash flow was about $2.1 billion in FY2025, Biogen's Q4 FY2025 earnings release states.
What critics point to
- Multiple sclerosis medicines brought in $919 million in Q3 FY2026, down from $1.06 billion a year earlier. Generic TECFIDERA and a TYSABRI biosimilar compete with them.
- The tiered royalty on US OCREVUS sales falls by 50% once the first FDA-approved OCREVUS biosimilar launches. The OCREVUS royalty was $1.41 billion in FY2025.
- Net debt was about $6.4 billion at Sep 30, 2026, up from about $2.0 billion at Dec 31, 2025, Biogen's earnings releases say.
- Biogen reported a net loss of $20.6 million in Q3 FY2026, a quarter with $283.8 million of acquired research and milestone costs.
- Revenue was $11.0 billion in FY2021 and $9.9 billion in FY2025.
10What to watch next
What should you watch next at Biogen?
Next event
Q4 FY2026 results
Date not announced yet.
Lupus trial results
Biogen said on Oct 28, 2026 that Phase 3 results for litifilimab in lupus (TOPAZ-1 and TOPAZ-2) are due in the first half of December 2026.
MS sales each quarter
MS medicines brought in $919 million in Q3 FY2026, against $1.06 billion a year earlier. Biogen said in its FY2025 10-K that it expects MS revenue to keep declining.
An OCREVUS biosimilar
Once the first FDA-approved OCREVUS biosimilar launches, the tiered royalty on US OCREVUS sales falls by 50%. The OCREVUS royalty was $1.41 billion in FY2025.
SYFOVRE sales and debt
SYFOVRE sold $191.3 million in Q3 FY2026, and its sales set whether former Apellis holders get up to $4.00 more per share. Net debt was about $6.4 billion at Sep 30, 2026.
11Key dates
What are the key dates for Biogen?
| Event | Date | Source |
|---|---|---|
| Litifilimab Phase 3 lupus results (TOPAZ-1 and TOPAZ-2)Due in the first half of December 2026, Biogen said on Oct 28, 2026. | Not yet stated | Q3 FY2026 earnings release (Form 8-K, Exhibit 99.1) |
| IMRALDI patent validity hearing in GermanySet for February 2027. | Not yet stated | Form 10-Q for Q3 FY2026 |
| SPINRAZA patent trial against Somerset and CiplaScheduled for May 2028. | Not yet stated | Form 10-Q for Q3 FY2026 |
12Key facts
Key facts about Biogen
- What does Biogen do?
- Biogen Inc. develops, makes and sells prescription medicines, mostly for diseases of the brain and nerves such as multiple sclerosis (MS) and spinal muscular atrophy. Its MS medicines brought in $4.04 billion of its $9.89 billion revenue in FY2025.
- How does Biogen make money?
- Biogen makes most of its money by selling its own medicines: product sales were 72.0% of its FY2025 revenue, 35.9% in the US and 36.1% elsewhere. Genentech's royalties and profit shares were 18.8%, contract manufacturing and royalties 7.4% and Biogen's LEQEMBI share 1.8% (Cityfort calculation from the FY2025 10-K).
- Who are Biogen's customers?
- In the US Biogen sells mainly to wholesale and specialty distributors and specialty pharmacies; elsewhere to wholesale distributors, hospitals, pharmacies and distribution partners. Two wholesale distributors together took about 43.9% of Biogen's gross product revenue in FY2025, and Genentech paid Biogen $1.86 billion that year.
- How big is Biogen?
- Biogen had revenue of $9.89 billion and net income of $1.29 billion in FY2025, and about 7,500 employees at Dec 31, 2025. In Q3 FY2026 Biogen's revenue was $2.80 billion, with a net loss of $20.6 million.
- Who owns Biogen?
- Biogen has one class of common stock and no controlling holder. Its 2026 proxy statementThe yearly filing about shareholder votes, the board and executive pay. Learn more lists PRIMECAP Management at 10.1% (13G/A filed Nov 13, 2025), BlackRock at 8.5% (Apr 17, 2025), FMR at 6.4% (Feb 5, 2026) and State Street at 5.0% (Nov 10, 2025). Biogen's directors and executive officers held about 0.2% on Apr 21, 2026 (Cityfort calculation from the proxy).
- Does Biogen pay a dividend?
- Biogen has never paid a cash dividend. Its 2020 buyback program allows up to $5.0 billion of share repurchases, and about $2.1 billion of it was left at Dec 31, 2025.
- What did Biogen buy in 2026?
- Biogen bought Apellis Pharmaceuticals on May 14, 2026 for $41.00 a share in cash, about $5.3 billion. The deal added the eye drug SYFOVRE and the rare-disease drug EMPAVELI, which sold $191.3 million and $51.5 million in Q3 FY2026.
- How much debt does Biogen have?
- Biogen's Q3 FY2026 earnings release puts its debt at about $7.7 billion and its net debt at about $6.4 billion at Sep 30, 2026. Its Q4 FY2025 release put net debt at about $2.0 billion at Dec 31, 2025.
Terms on this page
- Capital expenditures (capex)
- Debt-to-equity
- Earnings per share (EPS)
- EBITDA
- Free cash flow
- Net debt
- Net margin
- Revenue vs net income
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
13What it sells
13What it sells
What does Biogen sell?
Multiple sclerosis medicines
TYSABRI, VUMERITY, TECFIDERA, AVONEX and PLEGRIDY, sold to treat MS. Together they brought in $4.04 billion in FY2025, down from $4.66 billion in FY2023.
SPINRAZA
A drug for spinal muscular atrophy (SMA), an inherited disease that weakens muscles. Sales were $1.55 billion in FY2025; the FDA approved a higher-dose regimen in March 2026.
SKYCLARYS and QALSODY
SKYCLARYS treats Friedreich ataxia, a rare inherited nerve disease, and came with the 2023 purchase of Reata. QALSODY treats a genetic form of ALS (SOD1-ALS). FY2025 sales were $520.5 million and $86.9 million.
SYFOVRE and EMPAVELI
Bought with Apellis in May 2026. SYFOVRE treats geographic atrophy, an immune-driven disease of the retina; EMPAVELI treats a rare blood disorder (PNH) and two kidney diseases. They sold $191.3 million and $51.5 million in Q3 FY2026.
LEQEMBI
An Alzheimer's antibody developed and sold with Japan's Eisai. Biogen books its 50% share of the partnership's revenue and costs, $177.7 million in FY2025.
ZURZUVAE
A pill for postpartum depression, sold in the US with Supernus, which takes half of the US profit or loss. Sales were $195.1 million in FY2025.
Biosimilars
Near-copies of other companies' biologic drugs (medicines made in living cells), such as BENEPALI and IMRALDI, sold by Biogen mostly in Europe; Samsung Bioepis makes IMRALDI. Sales were $729.1 million in FY2025.
Anti-CD20 programs with Genentech
A royalty on US sales of Genentech's MS drug OCREVUS ($1.41 billion in FY2025) plus a share of US profits on RITUXAN, GAZYVA and LUNSUMIO ($420.2 million).
What it does
- Does: Sells its own medicines through wholesalers, specialty distributors and specialty pharmacies in the US, and through its own sales teams worldwide.
- Does: Collects a tiered royalty from Genentech on US sales of OCREVUS, from 13.5% up to 24.0%.
- Does: Makes biologic drugs in its own plants, including a large plant in Solothurn, Switzerland, and makes drugs for other companies under contract.
What it does not do
- Does not: Does not sell OCREVUS itself: Genentech sells it and pays Biogen a royalty.
- Does not: Does not book all of LEQEMBI's sales: Eisai records them, and Biogen books half of the partnership's revenue and costs.
- Does not: Does not sell biosimilars much in the US: $13.7 million of the $729.1 million in FY2025 came from US sales.
14How the money flows
14How the money flows · FY2025
How does money flow through Biogen?
Money in
- Total revenue (medicines, Genentech payments, LEQEMBI share, manufacturing and royalties)$9.9B
The company
Biogen
$9.9B came in
Money out
- Cost of sales (making and supplying medicines, royalties paid)$2.4B
- Research and development, incl. $471.8M for bought-in drug programs$2.3B
- Selling, general and administrative$2.4B
- Amortization of bought drug rights, partner profit shares and other charges$940M
- Other expense, net (interest and investment results)$306M
- Income tax$264M
- Net income$1.3B
- Customers and partners paid Biogen $9.89 billion in FY2025; $7.12 billion was for its own medicines.
- Making and supplying the medicines took $2.40 billion.
- Research took $2.25 billion, including $471.8 million paid for drug programs bought from others. Selling and administration took $2.43 billion.
- Amortization of drug rights bought in past deals ($515.0 million), partners' profit shares, restructuring and write-downs took $940.3 million more. Interest and other items took $305.6 million.
- Tax took $263.6 million, and $1.29 billion was left as net income.
Sources (1)
15What it needs to run
15What it needs to run
What does Biogen need to run?
Research and bought-in drug programs
New drugs replace old ones whose patents end. Biogen spent $1.78 billion on research and $471.8 million on acquired programs in FY2025, and bought RayThera in August 2026.
Patents and orphan drug status
Patents, and orphan drug status for rare-disease medicines, keep copies off the market for a time. SPINRAZA has orphan drug designation in the US, the EU and Japan; SKYCLARYS and QALSODY in the US and the EU.
Biologics plants
Its Solothurn, Switzerland plant is approved to make LEQEMBI and TYSABRI. About $2.0 billion of its $3.32 billion of long-lived assets related to Solothurn at Dec 31, 2025.
Partners
Genentech (OCREVUS royalty), Eisai (LEQEMBI), Supernus (ZURZUVAE) and Samsung Bioepis (biosimilars) each share revenue or profit with Biogen.
People
About 7,500 employees at Dec 31, 2025.
Sources (2)
16Where it sells
16Where it sells · FY2025
Where does Biogen sell?
- United States (share of product revenue)49.8%
- Europe excluding Germany (share of product revenue)26.3%
- Germany (share of product revenue)12%
- Asia (share of product revenue)5.9%
- Other regions (share of product revenue)6%
Sources (1)
17Competitors and what protects it
17Competitors and what protects it
Who does Biogen compete with?
Eli Lilly and Company
NYSE: LLY
Its Alzheimer's drug KISUNLA, approved in the US in 2024 and the EU in 2025, competes with LEQEMBI, the 10-K says.
EVRYSDI and ZOLGENSMA (SMA treatments)
The 10-K names this oral drug and this gene therapy as competitors to SPINRAZA, and expects them in more countries.
Generic TECFIDERA makers (e.g. Neuraxpharm)
Generic versions sell at deep discounts in North America, Brazil and parts of Europe. Biogen has sued some makers, including Neuraxpharm, for damages over EU sales.
TYSABRI biosimilar
A biosimilar of TYSABRI was approved in the US and the EU in 2023. Biogen said in its Q3 FY2026 10-Q (Oct 28, 2026) that it expects the biosimilar to keep hurting TYSABRI sales.
Somerset Therapeutics and Cipla
Biogen sued both in May and June 2026 under the Hatch-Waxman Act over SPINRAZA patents; trial is scheduled for May 2028.
What protects the business
Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.
- Patents and orphan drug status3 of 5
SPINRAZA has orphan drug designation in the US, the EU and Japan, and SKYCLARYS and QALSODY in the US and the EU. TECFIDERA shows the limit: its sales fell from $1.01 billion in FY2023 to $680 million in FY2025 as generics spread.
- Biologics manufacturing3 of 5
It owns large plants, including Solothurn in Switzerland, approved to make LEQEMBI and TYSABRI, and earned $732.9 million in FY2025 from contract manufacturing, royalties and other revenue.
- Partner income3 of 5
The Genentech programs paid $1.86 billion in FY2025 without Biogen selling those drugs, but the OCREVUS royalty halves when the first FDA-approved OCREVUS biosimilar launches.
Weak spot
Aging MS medicines
MS drugs were 56.7% of FY2025 product revenue, and MS revenue fell from $4.66 billion in FY2023 to $4.04 billion in FY2025. Management said in the FY2025 10-K that it expects MS revenue to keep declining.
Sources (2)
18Where growth could come from
18Where growth could come from
Where could Biogen's growth come from?
Biogen said in its Q3 FY2026 earnings release (Oct 28, 2026) that it expects FY2026 total revenue to rise by a mid-single-digit percentage from 2025, and non-GAAPThe company's own "adjusted" numbers, not the official (GAAP) ones. Always read them next to the official figure. Learn more diluted EPS (Biogen's adjusted profit per share) of $12.20 to $13.00. That EPS range includes about $3.20 per share of acquired research, upfront and milestone costs and $0.55 of expected dilution from Apellis. On Feb 6, 2026, before agreeing to buy Apellis, it had said revenue would fall by a mid-single-digit percentage and non-GAAP EPS would be $15.25 to $16.25.
SPINRAZA higher dose
Working$461M in Q3 FY2026, up from $374M
The FDA approved a higher-dose regimen in March 2026. In its Q3 release Biogen said conversion to it "continues to exceed Company expectations".
Status: Working, on track against what the company said.
Apellis medicines (SYFOVRE, EMPAVELI)
New$243M of revenue in Q3 FY2026
Bought on May 14, 2026 for $41.00 a share in cash, about $5.3 billion, plus a right to up to $4.00 more per share if SYFOVRE sales pass set levels.
Status: New, recently announced.
LEQEMBI (with Eisai)
WorkingBiogen's share $68M in Q3 FY2026, up from $43M
Eisai recorded global LEQEMBI sales of $202 million in Q3 FY2026, up from $121 million. The FDA approved an under-the-skin autoinjector for the starting dose in July 2026.
Status: Working, on track against what the company said.
SKYCLARYS
Working$178M in Q3 FY2026, up from $133M
Came with Reata in September 2023. Yearly sales rose from $55.9 million in FY2023 to $520.5 million in FY2025.
Status: Working, on track against what the company said.
ZURZUVAE
Working$84M in Q3 FY2026, up from $55M
Approved in the US in August 2023 and the EU in September 2025. Supernus shares half of the US profit or loss.
Status: Working, on track against what the company said.
Late-stage pipeline
EarlyLupus results due first half of Dec 2026
Biogen said on Oct 28, 2026 that Phase 3 results for litifilimab in lupus (TOPAZ-1 and TOPAZ-2) are due in the first half of December 2026, with felzartamab results in the first half of 2027.
Status: Early, too early to judge.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
19The company's own measures (non-GAAP)
19The company's own measures · FY2024, FY2025 and Q3 FY2026
What do Biogen's own measures show?
Official (GAAP): Diluted EPS, FY2025
$8.79
Company's own measure: Non-GAAP diluted EPS, FY2025
$15.28
Biogen leaves out acquisition costs such as amortization of drug rights and inventory step-up, restructuring, and gains or losses on equity investments.
Official (GAAP): Diluted EPS, FY2024
$11.18
Company's own measure: Non-GAAP diluted EPS, FY2024
$16.47
Same type of exclusions.
Official (GAAP): Diluted EPS, Q3 FY2026
−$0.14
Company's own measure: Non-GAAP diluted EPS, Q3 FY2026
$2.62
Same type of exclusions, including Apellis deal costs. Both figures include $284 million of acquired research and milestone costs, mainly for RayThera.
These are the company's own measures, defined by the company. They are not comparable across companies, and they are not added together. Each sits beside the nearest official (GAAP) figure.
Learn: Non-GAAP measures: what a company's "adjusted" numbers leave out
20Financial strength and debt
20Financial strength · Sep 30, 2026
How much debt does Biogen have?
- Total debt$7.7B
- Cash and investments$1.3B
- Net debt (debt minus cash)$6.4B
- Net worth (shareholders' money)$18.9B
- Debt to equity
- 0.41×
- $ of debt for every $1 of shareholders' money
- Biogen's Q3 FY2026 earnings release puts debt at about $7.7 billion and cash and cash equivalents at about $1.3 billion at Sep 30, 2026. The Q3 FY2026 10-Q shows $7,292.0 million of notes payable plus a $400.0 million current portion of notes and term loan, and no marketable securities that day.
- At Dec 31, 2025 Biogen had about $4.2 billion of cash, cash equivalents and marketable securities and about $6.3 billion of debt, its Q4 FY2025 earnings release and Q3 FY2026 10-Q state. The FY2025 10-K shows $6,286.8 million of notes.
- Biogen paid for Apellis with cash and marketable securities, a $2.0 billion term loan and a $400.0 million draw on its revolving credit line, the Q3 FY2026 10-Q says.
- It also took over Apellis's term loan with Sixth Street Lending Partners, about $395.2 million including interest and prepayment fees, and repaid it in full in Q2 FY2026.
- At Dec 31, 2025 Biogen's seven series of notes carried interest rates from 2.250% (due 2030) to 6.450% (due 2055). Interest expense was $267.5 million in FY2025.
- Of the $6,567.3 million of note principal at Dec 31, 2025, none was due from 2026 to 2029, $1,500.0 million was due in 2030 and $5,067.3 million in 2031 or later, the FY2025 10-K shows.
- Goodwill and intangible assets were $20.4 billion, 63.6% of total assets of $32.1 billion at Sep 30, 2026. Debt was 0.41 times equity. Both are Cityfort calculations from the Q3 FY2026 10-Q.
21Who owns it
21Who owns it · ownership as of Apr 21, 2026
Who owns Biogen?
- Officers and directors (as a group), shares
- 0.2%
Share classes
Holders of 5% or more
From the company's proxy statement (DEF 14A), later Schedule 13G filings and the share counts on its latest annual or quarterly report. Each holder row shows the date of its own filing.
Learn: How to read a proxy statement (DEF 14A): Nvidia's 2026 proxy · Form 4 insider filings: who files, the codes and the footnotes
22What it does with profit
22What it does with profit
What does Biogen do with its profit?
No buybacks or fund raises in the period covered.
23Governance signals
23Governance signals
What do Biogen's governance filings show?
- Auditor
- PricewaterhouseCoopers LLP, since 2003
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- The 2026 proxy statement describes a written policy under which the board's Corporate Governance Committee must review and approve any transaction in which a director, executive officer or family member has a material interest.
- Credit rating
- Not checked for this page
Flags to know about
other · Oct 28, 2026
Securities class actions
Biogen and some current and former officers are or were defendants in four securities actions. They allege violations of federal securities laws over statements about ADUHELM, LEQEMBI, TECFIDERA and VUMERITY, and statements Apellis made about SYFOVRE. According to the Q3 FY2026 10-Q, in September 2026 a court gave final approval to the settlement of one action and in October 2026 preliminary approval to the settlement of another. One action was dismissed in March 2026 and the appeal continues; in August 2026 an appeals court affirmed the dismissal of another.
other · Oct 28, 2026
IMRALDI patent dispute in Europe
Fresenius Kabi alleges that IMRALDI infringes its EP '488 patent. It seeks about EUR 19.1 million in damages in France, and a German validity hearing is set for February 2027.
24How it got here
24How it got here
How did Biogen get here?
1978
Milestone
Founded
Biogen was founded in 1978.
2023
Business-model change
Fit for Growth and Reata
Started Fit for Growth, a cost program, and in September bought Reata, which brought SKYCLARYS.
2023
Crisis
TYSABRI biosimilar approved
A copy of TYSABRI, its biggest MS drug, was approved in the US and the EU.
2025
Crisis
TECFIDERA patent revoked in Europe
In November 2025 the European Patent Office revoked a TECFIDERA patent, and Biogen stopped enforcing it and its national counterparts.
2026
Milestone
SPINRAZA higher dose approved
The FDA approved a higher-dose SPINRAZA regimen in March 2026.
2026
Business-model change
Apellis bought
Closed the Apellis deal on May 14, 2026, adding SYFOVRE for an eye disease and EMPAVELI for rare blood and kidney diseases.
25Sources and changes
Where every number on this page comes from
Sources (22 documents)
- S1Form 10-Q for Q3 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Oct 28, 2026
- S2Form 10-Q for Q2 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Jul 29, 2026
- S3Form 10-Q for Q1 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Apr 29, 2026
- S4Form 10-K for FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Feb 6, 2026
- S5Form 10-Q for Q3 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Oct 30, 2025
- S6Form 10-Q for Q2 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Jul 31, 2025
- S7Form 10-Q for Q1 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · May 1, 2025
- S8Form 10-K for FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Feb 12, 2025
- S9Form 10-Q for Q3 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Oct 30, 2024
- S10Form 10-Q for Q2 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Aug 1, 2024
- S11Form 10-Q for Q1 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Apr 24, 2024
- S12Form 10-K for FY2023 · SEC EDGAR · Tier 1: company or exchange filing · Feb 14, 2024
- S13Form 10-K for FY2022 · SEC EDGAR · Tier 1: company or exchange filing · Feb 15, 2023
- S14Form 10-K for FY2021 · SEC EDGAR · Tier 1: company or exchange filing · Feb 3, 2022
- S15Proxy statement (DEF 14A) for the 2026 annual meeting · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Apr 28, 2026
- S16Q3 FY2026 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Oct 28, 2026
- S17Q2 FY2026 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Jul 29, 2026
- S18Q1 FY2026 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Apr 29, 2026
- S19Q4 FY2025 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Feb 6, 2026
- S20Q4 FY2024 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Feb 12, 2025
- S22Form 8-K: Apellis acquisition completed, CVR agreement and credit agreement · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · May 14, 2026
- S23Form 8-K: board chair change (Items 5.02 and 8.01) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Feb 11, 2026
Changes to this page (v1 · Nov 20, 2026)
- v1 · Nov 20, 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.